Executive Briefings | July 31, 2019
What Do ‘Breakthrough Mental Health Medications’ Mean For Practice?
Of the many developments in the complex consumer market, anticipating the likely market effects of new treatments is the most difficult. The difficulty is all in that pesky “time lag”—it takes 15 to 20 years from science to service (see Failure To Launch). There are three new mental health medications that caught my eye as having big benefits for consumers—Esketamine nasal spray, Brexanolone injection for intravenous use, and SEP-363856 (in development for schizophrenia).
Esketamine nasal spray—On March 5, 2019, the . . .